BSX
BOSTON SCIENTIFIC CORPPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 19 to May 20 ▲ 2 days of insider buys: $554.0K by 3 insiders, avg $56.53
- May 27 to Jun 5 ▼ 3 sells: Ro Khanna, John Boozman and 1 more sold $1,001 - $15,000, last disclosed Jul 13
- May 29 to Jun 5 ▲ 3 buys: Gilbert Cisneros, Ro Khanna bought $1,001 - $15,000, last disclosed Jul 8
- Jul 8 to Jul 10 3 court rulings: Hansen v. Boston Scientific Corp. et al; Greenberg v. Boston Scientific Corporation et al and 1 more
- Jul 31 to Aug 5 ▲ 4 days of insider buys: $9.4M by 3 insiders, avg $48.25
- Aug 10 to Aug 18 ▲ 2 buys: Ro Khanna, Gilbert Cisneros bought $1,001 - $15,000, last disclosed Sep 11
- Aug 25 ▲ 1 insider buy $100.4K at $49.22
- Aug 31 to Sep 11 ▼ 5 sells: Kevin Hern, Ro Khanna sold, last disclosed Oct 9
- Aug 31 ▼ Short interest jumps 74.4% to 48.17M
- Oct 28 ▼ Boston Scientific reported Q3 2026 net sales of $5.138 billion, up 1…
- Oct 28 ▲ Earnings: BSX Q3 2026 Earnings: EPS $0.73 (+1.1% vs est)
- Oct 30 ▼ TD Cowen downgrades
Signal stack
Where each data set points today.
- InsidersBULLISH
5 insiders bought $10.0M at an average $48.65. No open-market sales. Price is 10% below their cost.
- InstitutionsMIXED
Q2 2026: 80 added (2 new), 97 trimmed or exited.
- AnalystsBULLISH
24 of 37 rate it Buy or better. Median target $49.00 (+12%).
- Short sellersSTEADY
Short interest −13.7% to 35.11M shares. 1.6 days to cover, ≈2.4% of shares.
- TrendRANGE
0% below its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | ADD | $2.2B |
| FMR LLC | TRIM | $2.0B |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | DOUBLED | $1.5B |
| JPMORGAN CHASE & CO | TRIM | $1.0B |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $994.2M |
| Capital Research Global Investors | DOUBLED | $605.3M |
| BANK OF AMERICA CORP /DE/ | TRIM | $556.0M |
| FIL Ltd | DOUBLED | $526.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
37 analystsPrice is inside the target range. Median implies +12%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 30, 2026 | TD Cowen DOWNGRADE | Hold |
| Oct 30, 2026 | Barclays MAINTAIN | Equal-Weight |
| Oct 29, 2026 | Jefferies DOWNGRADE | Hold |
| Oct 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 29, 2026 | Bernstein MAINTAIN | Outperform |
| Oct 29, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Mahoney Michael F Chairman, President & CEO Nov 4, 2026 | GIFT | 102,249 sh |
Mahoney Michael F Chairman, President & CEO Nov 4, 2026 | GIFT | 149,992 sh |
O'Sullivan Miriam SVP, Chief HR Officer Nov 1, 2026 | TAX W/H | $78.6K |
O'Sullivan Miriam SVP, Chief HR Officer Nov 1, 2026 | EXERCISE | 3,871 sh |
O'Connor Padraig Andrew EVP, Global Operations Sep 2, 2026 | EXERCISE | 1,171 sh |
O'Connor Padraig Andrew EVP, Global Operations Sep 2, 2026 | TAX W/H | $27.4K |
Morano Susan E Director Aug 25, 2026 | BUY | $100.4K |
Woodworth Emily SVP, Global Controller and CAO Aug 11, 2026 | PLAN TRADE | $150.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
22 filings · 3 bullish · 7 bearish · 4 mixed · 8 neutral- BEARISH 8-KOct 28, 2026
Boston Scientific reported Q3 2026 net sales of $5.138 billion, up 1.5% YoY, missing the $5.05B…
The cybersecurity incident is a material headwind that has disrupted operations and is driving a sharp deceleration in revenue growth and a Q4 sales decline. Watch for updates on the pace of…
- BEARISH PRESS-RELEASEOct 28, 2026
Boston Scientific reported Q3 2026 adjusted EPS of $0.73, in line with the $0.72 consensus, on…
The Q4 revenue decline guidance is a sharp reversal from the low-single-digit growth trajectory and suggests lingering disruption from the cybersecurity incident or demand weakness. Monitor the Q4…
- BEARISH INST-CLUSTEROct 23, 2026
A mixed institutional cluster in BSX for Q3 2026 shows 6 buyers adding $140.1M in new positions…
The divergence between a few large accumulators (Assenagon, Parnassus) and multiple near-exits (Vontobel, Ninety One UK) creates an unusual signal. Monitor upcoming Q4 2026 13F filings to see if the…
- MIXED 8-KOct 7, 2026
Boston Scientific announced the promotion of Joe Fitzgerald to COO effective Jan 1, 2027, and a…
The COO appointment and segment restructuring signal a proactive operational response to the cybersecurity disruption, but the financial impact is still unfolding. Watch for the Q3 2026 earnings…
All BSX filing & press-release reports (22)
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- INST-CLUSTER reportOct 23, 2026
- 8-K reportOct 7, 2026
- 8-K reportSep 23, 2026
- COURT-RULING reportAug 31, 2026
- 8-K reportAug 26, 2026
- INST-CLUSTER reportAug 22, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 5, 2026
- 8-K reportJul 29, 2026
- COURT-RULING reportJul 27, 2026
- 8-K reportJul 27, 2026
- COURT-RULING reportJul 10, 2026
- COURT-RULING reportJul 8, 2026
- COURT-RULING reportJun 17, 2026
- CLUSTER reportMay 21, 2026
- 8-K reportMay 18, 2026
- 8-K reportMay 18, 2026
- DEFA14A reportMar 18, 2026
- INST-CLUSTER reportFeb 28, 2026